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Deterioration of kidney function is typically slow but progressive, and occurs in every 
person during aging. Fortunately, not everybody develops chronic kidney disease (CKD). 
Kidney disease is often diagnosed at a late stage, and not until renal function has dropped 
below 10% of normal values, replacement therapy is needed. Kidney transplantation is a long-
term solution but is often not possible because of the shortage of donors. Therefore, CKD 
patients often receive dialysis therapy, which is life-saving, but falls short of long-term efficacy, 
resulting in a diminished quality of life for these CKD patients. Accordingly, new therapies are 
needed.  
The objective of the research described in this thesis is to develop new therapies for CKD 
patients using regenerative medicine strategies. Two approaches were taken: kidney cell-based 
membranes were bioengineered in vitro in order to ultimately ameliorate hemodialysis, and 
intrarenal anti-inflammatory drug delivery was applied to in-vivo regenerate the kidney. As 
scaffold/carrier materials we used supramolecular polymers which are dynamic in nature, and 
are easy to tune in a modular way by incorporation of bioactivity. Besides that, depending on 
the chemistry used, these supramolecular polymers could be applied as solid materials (used to 
bioengineer membranes) and as hydrogels (applied as intrarenal drug delivery vehicles). 
In the first chapter, the interdisciplinary field of kidney regenerative medicine is 
introduced thereby discussing the engineering concepts that are currently applied to regenerate 
or engineer renal tissue. Cells, materials and regenerative bioactive factors or a combination of 
these, are applied, thereby using the ‘renal regenerative niche’ as a source of inspiration. The 
second chapter introduces several supramolecular materials that are used for different tissue 
engineering applications. The chapter primarily focuses on supramolecular polymers in which 
the monomeric units are held together by hydrogen bonds, and then in particular by the four-
fold hydrogen bonding ureido-pyrimidinone (UPy) moiety. A modular approach to bioactive 
biomaterials is discussed in which supramolecular UPy-polymers are mixed with bioactive 
peptide sequences functionalized with the same supramolecular UPy-unit. Additionally, we 
show an in-vivo experiment in which several bioactive UPy-disks were implanted 
subcutaneously. It was demonstrated that the foreign body response to these materials is mild, 
and that the nature of the tissue response is changed with respect to the different UPy-peptides 
present in the disks.  
Chapters 3 and 4 describe the bioengineering of cell-based membranes that in future 
may be used in a bioartificial kidney device to ameliorate dialysis. The cells cultured on the 
synthetic supramolecular materials (that were introduced in chapter 2) electrospun into 
membranes were isolated from nephrectomized kidneys. Characterization showed that the 
isolated human primary tubular epithelial cells (PTEC) are a heterogeneous population 
consisting of at least, proximal and distal tubular cells, and collecting duct cells. The 
maintenance of a monolayer of kidney epithelial cells is important to achieve specific epithelial 
cell functions (and therefore the possibility to transport uremic toxins). The experiments in 




commercially available membranes with respect to the ability of the PTEC to form polarized 
monolayers on the supramolecular membranes. 
Bioactivity was introduced into these supramolecular membranes by means of 
extracellular matrix (ECM) derived peptide sequences modified with UPy-units. These ECM-
derived UPy-peptides were proposed to be incorporated in the supramolecular nanofibers 
formed by the base supramolecular polymers. Electrospinning of solutions containing both the 
UPy-polymers and the UPy-peptides resulted in micrometer thick electrospun fibers composed 
of bioactive supramolecular nanofibers. This led to a hierarchical supramolecularly structured 
membrane which could be applied as synthetic bioactive basement membrane. PTEC formed 
tight monolayers when cultured on these bioactive membranes for a long-term culturing period 
of 19 days. On the contrary, after this extensive culturing time, PTEC cultured on non-active 
control membranes lost their monolayer integrity, indicating the importance of the bioactive 
ECM-derived peptides. These experiments lay a foundation for application of the bioactive 
supramolecular membranes in a bioartificial kidney device and/or in a nephrotoxicity test 
system.  
To mimic the transition between blood vessel and tubular system more accurately, the 
presence of endothelial cells at the blood side of the synthetic basement membranes may be 
important, thereby influencing the phenotype and function of the epithelial cells at the pre-urine 
side. In chapter 5 the use of two different endothelial cell sources to be applied in a two-layered 
bioartificial kidney set-up are discussed. Endothelial progenitor cells derived from the blood of 
CKD patients showed diminished adhesion and proliferation on supramolecular films (which 
are the base materials described in chapters 3 and 4), making these cells less suitable for 
application in a bioartificial kidney at the blood side. In contrast, endothelial cells isolated from 
nephrectomized kidneys, in a similar manner as performed for the epithelial cells, PTEC, were 
able to adhere and to grow on both non-active and bioactive supramolecular films. It is 
proposed that these primary endothelial cells may be a source to be used in a bioartificial 
kidney. 
The second renal regenerative medicine strategy, in which intrarenal anti-inflammatory 
drug delivery was applied for in-vivo kidney regeneration, is described in chapters 6, 7 and 8. 
First the tissue response to and the influence of, three different supramolecular UPy-hydrogel 
carrier materials when implanted under the capsule of healthy rat kidneys, were investigated in 
chapter 6. The overall tissue response to these hydrogels is mild and minimal damage to the 
cortex was observed. Differences between the three hydrogels with respect to the nature of the 
tissue response are attributed to their different physico-chemical properties. The two strong, 
flexible hydrogels did not erode after two weeks of implantation. The tissue response to the 
more flexible hydrogel was located at the interface between kidney tissue and hydrogel, 
whereas the tougher hydrogel also induced slight damage to the kidney cortex. The third 
hydrogel which is weaker and softer than the two described above, eroded fast, within days. 
This is proposed to occur by dissolution of entire polymer aggregates. This third hydrogel 
showed a minimal tissue response which was comparable to the control kidneys in which only 
the renal capsule was loosened. The strong, flexible and slow degrading hydrogels are proposed 
to be suitable for long-term delivery of organic drugs, while the weaker, soft and fast eroding 
hydrogel may be used for short-term, fast delivery of proteinaceous drugs. 
In chapter 7, this third soft hydrogel was used to incorporate the anti-inflammatory and 
anti-fibrotic growth factor protein bone morphogenetic protein 7 (BMP7). BMP7 has anti-




activity through its antagonistic action of transforming growth factor beta (TGF). The soft 
supramolecular hydrogel could be easily loaded with BMP7 by simply mixing without the use 
of organic solvents. This allowed for the preservation of the biological activity of the hydrogel. It 
was proposed that while implanted under the kidney capsule, the in-vivo release of BMP7 is 
caused by erosion of both the protein and the hydrogel by dissolution. It was shown that local 
BMP7 delivery from this hydrogel carrier subcapsularly implanted in the kidney, resolved the 
slight cortical myofibroblast activation (chapter 7) as was seen when the placebo hydrogels 
(without BMP7) were implanted (chapter 6). These results support the proposal that this 
hydrogel-drug combination is suitable for intrarenal drug administration.  
The therapeutic effectiveness of this hydrogel-drug combination for short-term, 
immediate modulation of renal inflammation and ECM remodeling was tested in a rat model of 
acute kidney injury induced by uni-lateral ischemia/reperfusion in chapter 8. Subcapsular 
delivery of already a low amount (0.30 μg) of BMP7 led to a significant reduction in interstitial 
inflammatory and myofibroblast cell numbers. This shows that this approach is feasible and 
effective in the reduction of acute inflammation and incipient fibrosis. Therefore, this renal 
regenerative medicine strategy may find clinical application in renal transplant patients whose 
renal grafts develop post-operative ischemia/reperfusion injury. 
In conclusion, in this thesis we showed two different possibilities to kidney regenerative 
medicine that focus on in-vitro engineering of renal tissue, and on in-vivo kidney regeneration. 
The first strategy may be applied to ameliorate the conventional dialysis techniques, and the 
second approach may be used in kidney transplant patients. Importantly, to bring this relatively 
fundamental research into clinical practice close multi-disciplinary research and operations, e.g. 
intense collaborations between medical doctors, engineers, biologists and chemists, are 














In the Western world the amount of people with chronic kidney disease (CKD) is 
increasing every year.1 The progression of CKD into end-stage renal disease (ESRD) runs 
through four stages ending in the fifth, the ESRD stage.2 These stages are primarily defined 
based on glomerular filtration rate (GFR in mL/min/1.73 m2). In stage 1, GFR is 90 or above, 
and kidney function is slightly diminished. When GFR drops below 90, but stays above 60, stage 
2 is reached. In stage 3 there is a moderate reduction in GFR, which is between 30 and 60. Severe 
reduction of GFR is measured in stage 4 (15-30). In the early stages, kidney function is slightly 
deteriorated. This deterioration frequently remains unnoticed to patients. Therefore, CKD is 
often diagnosed at a late stage. This leads to dormant kidney function loss, which leaves little 
room for early intervention and possible regeneration strategies in vivo. When CKD is diagnosed 
early, medication aids against progression towards ESRD.  
However, when GFR ultimately drops below 15 mL/min/1.73 m2, the ESRD stage is 
reached, and renal replacement therapy is inevitable. Kidney transplantation provides a 
solution for long-term replacement of kidney function. Nevertheless, because of the shortage of 
sufficient donors, most ESRD patients receive dialysis therapy. Unfortunately, dialysis is life-
saving at short term, but falls short of long-term efficacy and most dialysis patients remain in 
poor health. Dialysis therapy does not substitute for important endocrine and metabolic 
functions critical for homeostasis, and uremic protein-bound waste products are not excreted. 
Consequently, innovative strategies towards new kidney therapies for patients with 
CKD or with ESRD3, based on regenerative medicine approaches4 are needed. In order to 
develop such strategies, knowledge on the ‘renal regenerative niche’ is necessary. This niche is 
formed by a close interplay between different cells, the extracellular matrix (ECM), and 
factors/signals (described in chapter 1). Possible strategies and new therapies based on renal 
regenerative medicine approaches are additionally described in chapter 1. Of course, the tissue 
engineering of a complete kidney in vitro which can be transplanted in vivo makes donor 
kidneys and/or dialysis therapy redundant.5 At present whole kidney engineering is not 
possible because the kidney is a very complex organ. However, a very recent study has shown 
that rat kidneys could be decellularized, reseeded with epithelial and endothelial cells, and 
cultured in whole-organ bioreactors.6 Orthotopic transplantation of these grafts showed 
excretory function in vivo.6  
Renal regenerative medicine approaches that focus on the improvement of dialysis 
therapy (i.e. engineering of a part of the kidney function) are more feasible to be clinically 
applied in the near future.3 A combination of conventional dialysis with cell-seeded membranes, 
so the development of a bioartificial kidney, may be a solution.7-8 Furthermore, the development 
of a wearable9 or implantable device10, with or without cells, is within reach. In early CKD 
phases, the stimulation of regeneration of the damaged kidney using stem cell techniques in 
combination with factors and/or materials is also a good option.5 
In this thesis we explore two renal regenerative medicine approaches. The first strategy 




dialysis using cell-based membranes to be applied in a bioartificial kidney in conjunction with 
the conventional dialysis apparatus. The bioartificial kidney concept was pioneered by Humes 
et al.7-8, who showed that renal function could be replaced in uremic dogs7, and that in 
preclinical and clinical studies this device has a potential to improve the renal function of 
patients with acute renal failure11-12. In our approach, described in this thesis, we introduced 
new supramolecular13-15 membranes, which can be produced by assembly of the base polymers 
and ECM-derived peptides, thereby mimicking the fibrous, hierarchical structure of the ECM 
(chapters 2, 3, and 4). Additionally, the source of human epithelial cells and endothelial cells to 
be applied on such membranes was studied (chapters 3, 4 and 5).  
The other, completely new, approach described in this thesis, consists of the local, 
intrarenal drug delivery of a proteinaceous anti-inflammatory and anti-fibrotic drug from a 
supramolecular hydrogel carrier implanted under the kidney capsule (chapters 6, 7 and 8). This 
may in future be applied for kidney transplantation patients, because 20% of the patients with a 
renal graft experience acute rejection within 5 years of transplantation.6 Furthermore, 
approximately 40% of the recipients will die or lose the renal graft within 10 years after 
transplantation. So, intrarenal drug therapy may be applied for renal transplantation patients 
who develop post-operative ischemia/reperfusion injury and/or severe inflammation leading 
to graft failure and/or rejection.  
 
RENAL CELL-BASED MEMBRANES FOR A BIOARTIFICIAL KIDNEY 
In our approach to renal cell-based membranes, supramolecular polymers were used to 
make electrospun meshes that can be used as membranes (chapters 3 and 4).13-15 Introduction of 
ECM-derived peptides16-17  into these supramolecular membranes through a modular 
approach18-19, and the proposed hierarchical, fibrous built-up of the membranes, have been 
shown to induce human primary tubular epithelial cells (PTEC) to form tight monolayers and 
maintain their epithelial phenotype and function (chapter 4). With the results and findings 
described in this thesis, we lay the basis for further (fundamental) research with respect to these 
supramolecular membranes in combination with human renal cells.  
Taking the ‘renal regenerative niche’ as an inspiration source, these cell-based 
membranes are proposed to be improved by not only using bioactive supramolecular 
membranes with four different ECM-derived peptides in combination with one type of kidney 
(epithelial) cells, but also by incorporating regenerative factors. The challenge is to rebuild this 
‘renal regenerative niche’ in vitro. 
With respect to the development of new membrane materials, it is important to elucidate 
the exact, complex composition of the basement membrane20-21 concerning its ECM components, 
such as laminin, collagen, agrin, perlecan, entactin/nidogen etc. Additionally, the amount of 
and the ratio between the components is important. The different ECM components are 
heterogeneously22 distributed along the tubule.23 This is different in nephrogenesis, and in a 
diseased situation, indicating the dynamic behavior of the ECM.22 Furthermore, the adhesion, 
proliferation and differentiation of renal cells on these synthetic basement membranes depends 
on different cell-surface (adhesion) receptors such as integrins, which are also different in the 
different parts of the tubular system.24 Others have shown the modification of hemodialysis 
membranes using different coatings such as ECM proteins25 and/or  3,4-dihydroxy-L-
phenylalanine26. Another option is the systematic variation of the composition of the 




bioactives. This may result in a better mimic of the synthetic basement membrane as part of this 
‘renal regenerative niche’.  
Along the tubule also, the (epithelial) cells are different in phenotype and function. 
Because we isolated epithelial cells from nephrectomised kidneys without sorting specific 
epithelial cell subsets, a heterogeneous population of PTEC (epithelial cells) was cultured on our 
cell-based membranes. The exact composition of this population is not known. Systematically 
varying the composition of the different epithelial cell types on the membranes may improve 
function of the construct. It has been shown, for example, that distal tubular cells influence 
potential survival of proximal cells after renal injury via expression of survival factors that can 
act on the proximal tubule.27 Alternatively, only one single epithelial cell type, the proximal 
tubular cell, has been suggested in literature to be applied in a bioartificial kidney.28 However, a 
combination of different cell types, e.g. epithelial cells, endothelial cells, stromal/interstitial and 
mesenchymal cells, may also improve function. Zink et al.29 and Repine et al.30 have shown that 
endothelial cells regulate PTEC function by cross talk. We showed that endothelial cells derived 
from nephrectomized kidneys may be a source to be used in a bioartificial kidney (chapter 5). 
These different cells can be possibly applied as mixtures at one side of the membrane or as co-
cultures with one (or more) types at both sides of the membrane. 
  As proposed above, regenerative factors may also influence and improve cell function. 
The proximal tubular cell performance in a bioartificial kidney clearly has shown to be 
improved by administration of recombinant bone morphogenetic protein 7 (BMP7).31 Even co-
culturing of these cells with BMP7-producing transfected cells have shown functional 
improvement.31 These studies show great promise for the administration of factors in a 
bioartificial kidney set-up. 
One of the major goals of a well-functioning bioartificial kidney set-up is middle-
molecule clearance and removal of protein-bound uremic toxins, e.g. p-cresol, indoxylsulfate, 
and homocysteine.32-33 The clearance of these toxins by the cell-based membranes developed in 
this thesis has to be investigated. Additionally, translation of the 2D membranes into a 3D 
configuration to test these cell-based membranes in conjunction with a dialysis machine also has 
to be performed.7-8  
In literature it is discussed that residual renal function (RRF) is important and associated 
with a decline in mortality.34 This is suggested to be caused by middle-molecule clearance and 
removal of uremic protein-bound toxins by RRF, which is not done by dialysis.34 Therefore, it is 
proposed that the addition of a bioartificial kidney to the conventional dialysis set-up may 
reduce mortality. Additionally, the bioartificial kidney may not only purify the blood but may 
also be designed that it induces kidney regeneration.  
 
LOCAL, INTRARENAL ANTI-INFLAMMATORY & ANTI-FIBROTIC DRUG DELIVERY 
In our approach to local, intrarenal drug delivery, a supramolecular hydrogel carrier 
loaded with a proteinaceous anti-inflammatory and anti-fibrotic drug was implanted under the 
kidney capsule (chapters 6, 7 and 8). The tissue response to placebo supramolecular hydrogels 
when subcapsularly implanted in rat kidneys is mild as investigated in chapter 6. The hydrogel 
that allowed for easy organic solvent-free loading of the growth factor protein BMP7 was 
chosen to be used as drug carrier (chapter 7). Intrarenal BMP7 delivery in a uni-lateral 
ischemia/reperfusion injury (IRI) model35-36 showed effective reduction of inflammation and 




This intrarenal drug delivery strategy is completely novel and has not been published 
before by others. On the contrary, the subcapsular implantation site is used for other purposes 
by others. For example, the influence of the site of implantation on the survival of islets 
embedded in hydrogels (taking the kidney capsule as a possible site) has been tested.37 Besides 
studies on islets also hepatocytes in matrigel have been subcapsularly implanted to study their 
ability to form liver tissue.38 
An alternative way of delivering drugs to the kidney is by active drug targetting.39 
Prevention of tubulointerstitial fibrosis in the kidney has been done by active targeting of kinase 
inhibitors to the kidney. For example, a Rho kinase inhibitor coupled to lysozyme has been 
released into proximal tubular cells in a transplantation model40, and dendrimers functionalized 
with sunitinib, a tyrosine kinase inhibitor, have also been shown to actively target to the 
proximal tubular cells. Other anti-fibrotic therapies use different delivery methods.41 For 
example, common anti-fibrotic drugs that are orally administered, such as pirfenidone42, may 
also act in on the kidney. Another example is the use of siRNA. Suppression of tubulointerstitial 
fibrosis was shown using siRNA against transforming growth factor beta (TGF) in a uni-lateral 
urether obstruction model.43  
While these renal anti-fibrotic drug delivery approaches appear to be simple, the 
opposite is true. The mechanism of fibrosis is very complex, as described before (chapter 8).44 
Many (protein) factors and processes play a role in the development of fibrosis, e.g. extensive 
matrix deposition, and the epithelial-to-mesenchymal transition (EMT).45 Delivery of 
proteinaceous drugs is not straightforward because of their ability to denature in many 
conditions thereby loosing the biological activity. However, to effectively intervene in the 
complex process leading to fibrosis, the use of protein factors that for example balance the 
matrix production and prevent EMT is an interesting strategy. In this thesis we investigated the 
intrarenal delivery of BMP7. BMP746 is a good target to be delivered in the kidney, because it is 
shown to play a role in EMT47, to act as antagonist of TGF48, to be a powerful renal 
morphogenic factor in kidney development49, and to have anti-inflammatory properties. We 
showed in chapter 8 that intrarenal BMP7 delivery significantly reduced interstitial 
inflammatory and myofibroblast cell numbers in an IRI model. More details on the distribution 
of the delivered BMP7, and on its action in time, are necessary to show the applicability. For 
example, BMP7 expression and activation in vivo have shown to be predominantly localized to 
the distal nephron.50 
The advantage of delivering proteins, via our local, intrarenal drug delivery approach, is 
the easy incorporation method of the protein into the hydrogel carrier by simple mixing. Besides 
that, because of local injection of the drug-loaded hydrogel, only low amounts of drug/protein 
are needed. These low amounts cannot be used with intraveneous and intraperitoneal injections. 
This gives the opportunity to test also other relevant proteins. In order to prevent renal fibrosis, 
inhibition of CTGF using antibodies may be an option.51 Another option may be the intrarenal 
delivery of interleukin 10 which has anti-inflammatory activity.52 In future, synthetic 
analogs/truncated peptides of large therapeutic proteins may also be delivered. For example 
Kalluri et al. have described the development of a 16 amino acid peptide which is a BMP7-








In this thesis we explored two renal regenerative medicine strategies. Other kidney 
regenerative medicine strategies have been investigated in literature, e.g. Atala et al. showed 
that it is possible to decellularize whole porcine kidneys54, and Ott and Vacanti et al. showed the 
regeneration and orthotopic transplantation of a bioengineered rat kidney6. The approaches 
explored by us that are described in this thesis, may also be used in other renal regenerative 
strategies. For example the solid supramolecular membranes may be applied in/as an 
implantable hemofilter10, or wearable kidney device.9,55-56 Ultimately, it might be possible to 
bioengineer a whole kidney using for example organ printing techniques57 using the solid 
supramolecular materials as scaffolds (instead of using decellularized kidney ECMs). The 
advantage of using these supramolecular materials lies in the possibility to apply different 
supramolecular building blocks with different biofunctionalities for the various parts of the 
kidney. Furthermore, the hydrogel carriers used in the intrarenal drug delivery approach may 
be used in regenerative approaches towards tubule58-59 and ultimately whole kidney 
engineering in vitro60-62. Inspiration from kidney development is needed to mimic the 
developmental renal niche in vitro.63 Different cells may be seeded in different supramolecular 
hydrogels with various bioactivities. The different cells that may be used are embryonic stem 
cells, adult Lgr5+ stem/progenitor cells64, induced pluripotent stem (iPS) cells, bone marrow 
derived cells, primary tubular epithelial cells.5 
The combination of all the kidney regenerative medicine approaches described and 
discussed may result in intelligent therapies that are CKD stage dependent. In this way renal 
replacement therapies will shift into kidney regeneration treatments in vivo. 
 
TOWARDS CLINICAL TRANSLATION? 
The research in this thesis has a clearly fundamental nature. It is not yet clinically 
applicable as such. The question is when the described renal regenerative medicine strategies in 
general can be translated, because in my opinion these research approaches have ambivalent 
goals. To improve cell function in a bioartificial kidney, for example, it is important to gain 
detailed understanding on the ‘renal regenerative niche’ to ultimately rebuild this niche in vitro. 
In order to do so, complexity has to be introduced in the in-vitro system, this means that not 
only bioactive cell adhesion signals need to be introduced in the scaffold membrane (as 
described in this thesis), but also regenerative factors. Besides that, it is also important how the 
molecules that make up the membrane are oriented and assembled. On the contrary, for clinical 
translation, the product (material, cell, factor and/or combination of these) has to be simple in 
composition and has to be applicable in a convenient way. It has been shown that new 
regenerative medicine concepts that are simple become a product more easily than complex 
concepts.65 
Another point which has to be taken into account in order to translate this research is the 
fact that the field of regenerative medicine is truly multi-disciplinary. Close collaborations 
between medical doctors, engineers, biologists and chemists are thus necessary. Bringing these 
different professionals together in such a way that they are able to speak the language of one 
another is a challenge. Not surprisingly, that one of my motives to perform the described 
research as a chemist in a medical center was to obtain knowledge of the different disciplines 
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